Skip to Main Content

WASHINGTON — Theranos, and the company’s notoriously inaccurate blood tests, could potentially have been stopped earlier if Congress had acted to fix a regulatory loophole.

Lawmakers are weighing now whether it’s better late than never.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment